ReviewFrontiers in pharmacology2025
Targeting the P2X7 receptor in cerebrovascular diseases: from molecular mechanisms to preclinical therapeutic potential.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- P2X7 Signaling in Neuroinflammation: Glial Crosstalk, Redox Integration, and Therapeutic Targeting.Journal of molecular neuroscience : MN · 2026Review
- Review
- P2X7 Receptor in Rare Diseases: Shared Molecular Mechanisms and Therapeutic Implications.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebrovascular diseases seriously damage human health and impose a huge burden on society. Research on the mechanisms of cerebrovascular disease occurrence and development is of great significance in preventing the occurrence of the disease and improving the quality of life of patients. P2X7 Receptor (P2X7R), as a non-selective cation channel of the purinergic receptor family, is considered to be expressed in various immune cells within the nervous system and may also be expressed in neurons. Recent studies have identified P2X7R as a significant player in the progression of cerebrovascular diseases, potentially linked to its role in regulating neuroinflammation, cellular autophagy, and vascular function. This review elucidates the biological foundation of P2X7R, compiles various molecular mechanisms associated with cerebrovascular diseases, emphasizes recent research on the involvement of P2X7R in the pathogenesis of cerebrovascular diseases, and assesses the pharmacological implications of P2X7R in these conditions. By exploring the connections between P2X7R and cerebrovascular diseases, the therapeutic potential of targeting P2X7R in these conditions can be assessed, ultimately paving the way for novel therapeutic strategies to ameliorate the impact of cerebrovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.